Integrated Financials as on 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Limited (BSE: 524590) submitted its integrated filing for FY25 with revenue from operations of Rs. 241.43 lakhs versus just Rs. 2.24 lakhs in FY24, swinging to a profit after tax of Rs. 16.39 lakhs (boosted by a Rs. 13.83 lakh deferred tax credit) from a prior-year loss of Rs. 26.41 lakhs. Despite the headline turnaround, the auditor M/s. Maak & Associates issued a Qualified Opinion because the company failed to provide balance confirmations for trade receivables (Rs. 251.75 lakhs) and trade payables — a repeating qualification from FY24. The company itself disclosed that accumulated losses exceed paid-up capital, net worth is negative at Rs. -15.15 lakhs, and operating cash flow was negative at Rs. -36.17 lakhs. Related party transactions include a Rs. 123.45 lakh loan from Managing Director Vishwambar Kameshwar Singh.
The headline jump to profit on a bigger revenue base looks positive on paper, but the small base, negative net worth, repeated audit qualification, negative operating cash flow, and explicit going-concern-style disclosures point to underlying financial weakness. Shareholders should treat this turnaround with caution and watch for follow-up confirmations, debt servicing, and audit clean-up before drawing comfort.